Alpa Laboratories Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Alpa Laboratories Ltd is ₹ 70.23 as of 06 May 15:30 . The P/E Ratio of Alpa Laboratories Ltd changed from 10.5 on March 2021 to 11.2 on March 2025 . This represents a CAGR of 1.30% over 5 yearsThe P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Alpa Laboratories Ltd changed from ₹ 76.06 crore on March 2021 to ₹ 219.07 crore on March 2025 . This represents a CAGR of 23.56% over 5 yearsThe Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Alpa Laboratories Ltd for the Dec '25 is ₹ 29.96 crore as compare to the Sep '25 revenue of ₹ 29.32 crore. This represent the growth of 2.18% The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Alpa Laboratories Ltd for the Dec '25 is ₹ 2.42 crore as compare to the Sep '25 ebitda of ₹ 0.82 crore. This represent the growth of 195.12% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Alpa Laboratories Ltd changed from ₹ 5.1 crore to ₹ 1.9 crore over 7 quarters. This represents a CAGR of -43.12% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Alpa Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 years .

About Alpa Laboratories Ltd

M/s Alpa Laboratories, formed in 1967, was incorporated as Private Limited Company in the name of Alpa Laboratories Private Limited on March 18, 1988 for manufacture of pharmaceutical formulations.
In 1998, the Company was converted into a Public Limited Company with effect from September 3, 1998 with the name of 'Alpa Laboratories Limited'.
The facility has dedicated manufacturing areas for different Finished Dosage Forms (FDFs) including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels. In 1997, the company has initiated setting of a new manufacturing unit at Rau(Indore District), Madhya Pradesh.
The unit commenced commercial production in the year 1999 of all types of formulations viz.
Injectables (Vials/Ampoules both liquid and Dry), tablets, capsules, eye/ear drops, ointment and creams.

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

FAQs for the comparison of Alpa Laboratories Ltd and Astrazeneca Pharma India Ltd

Which company has a larger market capitalization, Alpa Laboratories Ltd or Astrazeneca Pharma India Ltd?

Market cap of Alpa Laboratories Ltd is 147 Cr while Market cap of Astrazeneca Pharma India Ltd is 20,923 Cr

What are the key factors driving the stock performance of Alpa Laboratories Ltd and Astrazeneca Pharma India Ltd?

The stock performance of Alpa Laboratories Ltd and Astrazeneca Pharma India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alpa Laboratories Ltd and Astrazeneca Pharma India Ltd?

As of May 7, 2026, the Alpa Laboratories Ltd stock price is INR ₹70.23. On the other hand, Astrazeneca Pharma India Ltd stock price is INR ₹8369.45.

How do dividend payouts of Alpa Laboratories Ltd and Astrazeneca Pharma India Ltd compare?

To compare the dividend payouts of Alpa Laboratories Ltd and Astrazeneca Pharma India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.